Glenmark Pharmaceuticals ltd — Capital/Financing Update 2022

May 9, 2022

==> picture [16 x 10] intentionally omitted <==

==> picture [17 x 10] intentionally omitted <==

==> picture [140 x 42] intentionally omitted <==

May 09, 2022

To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%

With reference to the subject mentioned above, kindly find attached media release which is self‐explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Digitally signed by HARISH HARISH VINAYAK KUBER VINAYAK KUBER Date: 2022.05.09 08:45:34 +05'30' Harish Kuber

Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

For immediate distribution

==> picture [565 x 76] intentionally omitted <==

Press Release

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%

Mumbai, India, May 09 2022: Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar®[1] Foam, 0.005%|0.064%, of Leo Pharma AS.

According to IQVIA[TM ] sales data for the 12 month period ending March 2022, the Enstilar® Foam, 0.005%|0.064% market[2] achieved annual sales of approximately $115.2 million*.

Glenmark’s current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

-------End-------

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (Glenmark) is a global innovation-driven pharmaceutical company with presence across Specialty, Generics and OTC businesses. Globally, Glenmark focuses on the following key therapy areas: respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. It was ranked among the world’s top 50 Generics and Biosimilars companies (Top 50 Company Rankings, 2020, from Informa’s Generics Bulletin). The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the fourth consecutive year in a row, most recently in 2021. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index. www.glenmarkpharma.com

==> picture [561 x 28] intentionally omitted <==

==> picture [565 x 76] intentionally omitted <==

For more information, please contact:

Udaykumar Murthy

Deputy General Manager, Corporate Communications +91 9960377617 | corpcomm@glenmarkpharma.com

References:

• 1All brand names and trademarks are the property of their respective owners.

• 2Market includes brand and all available therapeutic equivalents

• *IQVIA[TM] National Sales Perspectives: Retail & Non-Retail, March 2022

==> picture [561 x 28] intentionally omitted <==